Under construction – not a live service
Sign in

NCT06168942Suspended

A Pivotal Investigational Device Exemption Study on Laminar Left Atrial Appendage Elimination

LAM202403: Laminar Left Atrial Appendage Elimination (LAAX) Pivotal IDE Study

Source: ClinicalTrials.gov · Last updated 19 Oct 2026

Reason given: Potential unwrapping of the LAA post implant with clinically significant leaks.

Brief summary (registry, in English)

The purpose of this study is to compare the safety and effectiveness of Laminar Left Atrial Appendage Closure (LAAC) device as compared to the commercially available LAAC devices in participants with non-valvular atrial fibrillation (NVAF) to reduce the risk of stroke (blocked blood vessel or bleeding in brain) and systemic embolism (blockage in a blood vessel harming vital organs).

Status (registry)
Suspended
Study type
Interventional
Enrollment
1500 (estimated)
First submitted
5 Dec 2023
Start date
19 Feb 2024
Primary completion date
1 Dec 2028
Lead sponsor
Jaguar LAA, Inc.
NCT number
NCT06168942

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Prior cardiac surgery or any procedure that involved pericardial access
  • Any cardiac or non-cardiac interventional or surgical procedures within 60 days prior to or any planned general surgery, cardiac surgery, or interventional procedure within 60 days after implant (including, but not limited to cardioversion, percutaneous coronary intervention (PCI), cardiac ablation, cataract surgery)
  • Left atrial appendage anatomy which cannot accommodate either commercially available control device or the laminar implant per manufacturer instructions for use (IFU) (that is, the anatomy and sizing must be appropriate for a control and the Laminar device to be enrolled in the study)

Other illness

  • Single episode, transient, or reversible atrial fibrillation (AF) (example, secondary to thyroid disorders, acute alcohol intoxication, trauma, recent major surgical procedures)

Lab values

  • Stage IV kidney disease or Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) less than (<) 30 milliliters per minute per (mL/min)/1.73 square meters (m\^2) or participants with end stage renal disease who are dialysis dependent

Who the study is looking for

  • Documented evidence of paroxysmal, persistent, or permanent non-valvular atrial fibrillation (NVAF)
  • CHA2DS2-VASc score greater than or equal to (>=) 2 in men and >= 3 in women
  • Deemed to be clinically indicated for left atrial appendage (LAA) closure by the Site Investigator and a clinician not a part of the procedural team using an evidence-based decision-making tool in accordance with standard of care
  • Recommended for chronic oral anticoagulation therapy (OAC) but has an appropriate rationale to seek a non-pharmacologic alternative
  • Eligible for the protocol-specified post-procedural antithrombotic regimen
  • Willing and able to comply with the protocol, and has provided written informed consent (participant or legally authorized representative) per institutional review board (IRB) requirements

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (36)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Piedmont HealthcareAtlantaUnited StatesUnknown status
Emory UniversityAtlantaUnited StatesUnknown status
Texas Cardiac Arrhythmia Research FoundationAustinUnited StatesUnknown status
Northwell HealthBay ShoreUnited StatesUnknown status
Grandview Medical CenterBirminghamUnited StatesUnknown status
Massachusetts General HospitalBostonUnited StatesUnknown status
Wake Forest University Health SciencesCharlotteUnited StatesUnknown status
Bethesda North Hospital TrihealthCincinnatiUnited StatesUnknown status
Lindner Clinical Trial Center/Christ HospitalCincinnatiUnited StatesUnknown status
Ohio State UniversityColumbusUnited StatesUnknown status
Ohio HealthColumbusUnited StatesUnknown status
Arrhythmia Research GroupJonesboroUnited StatesUnknown status
Baptist Health LexingtonLexingtonUnited StatesUnknown status
Cedars-Sinai Medical CenterLos AngelesUnited StatesUnknown status
Vanderbilt University Medical CenterNashvilleUnited StatesUnknown status
Centennial Medical CenterNashvilleUnited StatesUnknown status
Icahn School of Medicine at Mount SinaiNew YorkUnited StatesUnknown status
NYU Langone HealthNew YorkUnited StatesUnknown status
Columbia University in the City of New York and The New York and Presbyterian HospitalNew YorkUnited StatesUnknown status
Trident Medical CenterNorth CharlestonUnited StatesUnknown status
NCH HealthcareNorth NaplesUnited StatesUnknown status
The Kansas City Heart Rhythm InstituteOverland ParkUnited StatesUnknown status
Stanford Health CarePalo AltoUnited StatesUnknown status
Arizona Arrhythmia Research Group Phoenix Cardio Research Group PCRGPhoenixUnited StatesUnknown status
Univeristy of California Davis HealthRancho CordovaUnited StatesUnknown status
Scripps HealthSan DiegoUnited StatesUnknown status
Providence Saint John's Health Center and the Pacific Heart InstituteSanta MonicaUnited StatesUnknown status
Sarasota Memorial HospitalSarasotaUnited StatesUnknown status
Memorial Health University Medical CenterSavannahUnited StatesUnknown status
Swedish Medical CenterSeattleUnited StatesUnknown status
Heart Rhythm AssociatesShenandoahUnited StatesUnknown status
St Joseph Hospital and Medical CenterTacomaUnited StatesUnknown status
Montefiore Medical CenterThe BronxUnited StatesUnknown status
Los Robles Regional Medical CenterThousand OaksUnited StatesUnknown status
Tucson Medical CenterTucsonUnited StatesUnknown status
Ascension Via Christi Hospitals Wichita Inc.WichitaUnited StatesUnknown status

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.